Article
Top news of the week from Specialty Pharmacy Times
5. ZAP Gene is Crucial First Step in Cells Identifying HIV
A study sought to determine how HIV avoids the antiviral protein, zinc-finger antiviral protein. Read more.
4. Chemotherapy-Free Treatment Combo Achieves High Rates of MRD Negativity in CLL
A prospective analysis of the CLL14 trial showed that fixed-duration treatment of venetoclax plus obinutuzumab achieved high rates of undetectable minimal residual disease. Read more.
3. Gabapentinoids Prescriptions Grew Twofold in 10 Years
A study found that the total prescriptions for gabapentinoid medications grew from 1.2 million to 3.5 million between 2005-2015. Read more.
2. Mosunetuzumab Induces Complete Remissions in NHL After CAR T-Cell Therapy Relapse
A novel, off-the-shelf bispecific antibody could serve as a new treatment option for patients with non-Hodgkin lymphoma who don’t respond to CAR T-cell therapy. Read more.
1. Specialty Pharmacy Eases Financial Burden for Patients on Oral Therapies for Hematologic Malignancies
Patients receiving novel oral therapeutics often have a high dependence on financial assistance; specialty pharmacies may help facilitate access to these therapies. Read more.
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa